TSE:MDP Q2 EPS Estimate Boosted by Raymond James Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Raymond James Financial boosted their Q2 2026 EPS estimates for shares of Medexus Pharmaceuticals in a report issued on Wednesday, August 13th. Raymond James Financial analyst M. Freeman now expects that the company will earn $0.00 per share for the quarter, up from their prior estimate of ($0.07). The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James Financial also issued estimates for Medexus Pharmaceuticals’ Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.10 EPS, Q2 2027 earnings at $0.21 EPS, Q3 2027 earnings at $0.29 EPS, Q4 2027 earnings at $0.29 EPS, FY2028 earnings at $1.08 EPS, FY2029 earnings at $1.79 EPS and FY2030 earnings at $2.13 EPS.

Separately, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 11th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of C$5.49.

Medexus Pharmaceuticals Trading Down 3.4%

TSE:MDP opened at C$2.85 on Monday. The company has a market capitalization of C$63.81 million, a P/E ratio of 13.63 and a beta of 1.96. Medexus Pharmaceuticals has a 12 month low of C$1.71 and a 12 month high of C$5.56. The firm has a fifty day simple moving average of C$2.92 and a 200-day simple moving average of C$2.79.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.